The company said Peter Bains has resigned from the position of Managing Director and Chief Executive Officer with effect from the close of business hours on June 30, 2026.
Following his exit, the Board has appointed Siddharth Mittal as an Additional Director, designated as Managing Director and Chief Executive Officer of the company, with effect from July 1, 2026, subject to shareholders’ approval. His appointment will be for a period of five years.
Mittal will also serve as a member of the Executive Committee of the company.
Prior to this appointment, Siddharth Mittal served as Managing Director and Chief Executive Officer of Biocon Limited. He joined the company in May 2013 and held the role of President and Chief Financial Officer until November 2019.
He brings over two decades of experience in strategic finance, mergers and acquisitions, and general management. During his tenure, he contributed to the growth of the biosimilars business and its transition into Biocon Biologics in 2019.
Separately, the Board also approved a change in role for Kiran Mazumdar-Shaw from Non-Executive Chairperson to Executive Chairperson of the company, effective April 1, 2026, subject to shareholders’ approval. The appointment will be for a period of five years.
Also read: Syngene International Q3 Results: Net profit dives 89% on large-molecule biologics impact
Shares of Syngene International closed at ₹410.50 on the NSE, down ₹8.25 or 1.97%.
